Skip to content

OrthoPulse Gen 2 Initial Device Evaluation and Assessment of Clinical Effectiveness (CA)

RI.2 OrthoPulse Gen 2 Initial Device Evaluation and Assessment of Clinical

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04386278
Enrollment
56
Registered
2020-05-13
Start date
2020-01-08
Completion date
2020-06-24
Last updated
2020-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orthodontic Tooth Movement

Brief summary

This is a prospective, interventional, non-randomized, control, split-mouth, open-label, single centre, private practice study aimed to evaluate the effect of tooth movement during orthodontic treatment using a removeable thermoplastic orthodontic appliance. Intrusion and extrusion will be conducted using bilaterally equivalent elastomeric forces of 50 grams. A comparison of the rate of bilateral orthodontic tooth movement will be conducted using six (6) varied photobiomodulation interventions on the maxillary (upper) and mandibular (lower) arches. The OrthoPulse Gen 2 and OrthoPulse (commercially approved) devices are being used in this clinical investigation. Each subject enrolled will go through intrusion and extrusion. All subjects will be allocated to an OrthoPulse split-mouth intervention by the investigator.

Interventions

DEVICEIntervention 1

Side one: No treatment Side two: OrthoPulse Gen 2 (2RP) for one minute

DEVICEIntervention 2

Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for one minute

Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RP) for 5 minutes

Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (2RCW) for five minutes

DEVICEIntervention 5

Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute

DEVICEIntervention 6

Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for five minutes

DEVICEIntervention 7

Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RB 2RL) for one minute

DEVICEIntervention 8

Side one: OrthoPulse (approved device) Side two: OrthoPulse Gen 2 (3RBP) for five minutes

Sponsors

Biolux Research Holdings, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Each group in this study includes a different device iteration that is being investigated in parallel.

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patient must be 19 years of age or older * Likely to be compliant to OrthoPulse use, aligner wear, and Dental Monitoring scanning * Have a compatible iOS or Android device and are willing to download the OrthoPulse and Dental Monitoring apps for frequent automatic syncing of data

Exclusion criteria

* Patient is currently enrolled in another clinical study * Crowding or rotations of bilateral bicuspids that would prevent or interfere with intrusion * Periodontally involved teeth, acute oral infection or periodontal disease * Patient has active/untreated caries * Use of bisphosphonates at any time * Use of drugs that may cause photosensitivity * History of photosensitivity * Epilepsy * Pregnant or planning pregnancy during the study. * Patient plans to relocate over the treatment period

Design outcomes

Primary

MeasureTime frameDescription
The rate of orthodontic tooth movement36 days (±12 days) from T0 visitThe rate of orthodontic tooth movement during intrusion at 36 days (±12 days) from the T0 Visit (measured in mm per week).

Secondary

MeasureTime frameDescription
Peak Pain: Questionnaire7 DaysAssess peak pain experienced over first seven (7) days of treatment during intrusion using a questions similar in nature to a Visual Analog Scale (subject to complete pain questionnaire).
Root Resorption36 days (±12 days) from T0 visitAssess tooth resorption by measuring the root length of the first or second bicuspid bilaterally from baseline to T3
Initial Safety of DeviceFrom enrolment to study completion, anticipated six (6) monthsConfirmation of safety through collection of adverse events

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026